Edward van der Horst, Ph.D.
"For Sensei Biotherapeutics, obtaining clinical trial approval (IND) for our anti-VISTA SNS-101 antibody represents a significant milestone, and genOway's models have been critical in moving our program forward.
Assessment of SNS-101 in physiologically relevant and complementary preclinical models, such as the BRGSF-HIS and VISTA KI humanized mouse models, allowed us to further qualify the pharmacodynamics and toxicology of our first conditionally active antibody.
We are optimistic, based on the results obtained in animal studies, that SNS-101 antibody has the potential to achieve a higher therapeutic index and a more favorable safety profile than other drugs for patients with solid tumors."
Edward van der Horst, Ph.D.
Chief Scientific Officer at Sensei Biotherapeutics
